PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/110433

Please be advised that this information was generated on 2020-03-11 and may be subject to change.
Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial

Sepideh Saadatmand1*, Emiel JT Rutgers2, Rob AEM Tollenaar3, Hermien M Zonderland4, Margreet GEM Ausems5, Kristien BMI Keymeulen6, Margreet S Schlooz-Vries7, Linetta B Koppert1, Eveline AM Heijnsdijk8, Caroline Seynaeve9, Cees Verhoef1, Jan C Oosterwijk10, Inge-Marie Obdeijn11, Harry J de Koning8 and Madeleine MA Tilanus-Linthorst1

Abstract

**Background:** To reduce mortality, women with a family history of breast cancer often start mammography screening at a younger age than the general population. Breast density is high in over 50% of women younger than 50 years. With high breast density, breast cancer incidence increases, but sensitivity of mammography decreases. Therefore, mammography might not be the optimal method for breast cancer screening in young women. Adding MRI increases sensitivity, but also the risk of false-positive results. The limitation of all previous MRI screening studies is that they do not contain a comparison group; all participants received both MRI and mammography. Therefore, we cannot empirically assess in which stage tumours would have been detected by either test.

The aim of the Familial MRI Screening Study (FaMRIsc) is to compare the efficacy of MRI screening to mammography for women with a familial risk. Furthermore, we will assess the influence of breast density.

**Methods/Design:** This Dutch multicentre, randomized controlled trial, with balanced randomisation (1:1) has a parallel grouped design. Women with a cumulative lifetime risk for breast cancer due to their family history of ≥20%, aged 30–55 years are eligible. Identified BRCA1/2 mutation carriers or women with 50% risk of carrying a mutation are excluded. Group 1 receives yearly mammography and clinical breast examination (n = 1000), and group 2 yearly MRI and clinical breast examination, and mammography biennially (n = 1000).

Primary endpoints are the number and stage of the detected breast cancers in each arm. Secondary endpoints are the number of false-positive results in both screening arms. Furthermore, sensitivity and positive predictive value of both screening strategies will be assessed. Cost-effectiveness of both strategies will be assessed. Analyses will also be performed with mammographic density as stratification factor.

**Discussion:** Personalized breast cancer screening might optimize mortality reduction with less over diagnosis. Breast density may be a key discriminator for selecting the optimal screening strategy for women < 55 years with familial breast cancer risk; mammography or MRI. These issues are addressed in the FaMRIsc study including high risk women due to a familial predisposition.

**Trial registration:** Netherland Trial Register NTR2789

**Keywords:** Breast cancer, Familial risk, Screening, MRI, Breast density, Cost-effectiveness

* Correspondence: s.saadatmand@erasmusmc.nl
1Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
Full list of author information is available at the end of the article

© 2012 Saadatmand et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
A positive family history is one of the most important risk factors for breast cancer [1]. Women with a family history of breast cancer are not only at greater risk of developing breast cancer, but their risk also increases at a younger age than in the general population [2]. In over 75% of the families that display clear clustering of breast cancer no causative gene mutation like BRCA1 or BRCA2 can be detected [3]. Tumour stage at detection is of key influence on survival [4]. Aiming at early detection and ultimately to reduce mortality risk, women, with a positive family history for breast cancer, are often offered annual screening with mammography before age 50 [5-7]. However, screening also causes false-positive test results.

In the last decade several screening trials in high-risk women have been completed and Magnetic Resonance Imaging (MRI) had a significantly higher sensitivity for invasive breast cancer than mammography in all studies [8-12]. However, MRI was expensive and was associated with significantly more false-positive results in most studies. Furthermore, mammography had better sensitivity for the pre-invasive stage of breast cancer: ductal carcinoma in situ (DCIS) [13]. Therefore, mammography should perhaps not be omitted completely when MRI screening is offered.

Despite the higher costs of MRI and the false-positive results, screening with yearly MRI in addition to mammography is considered cost-effective for female BRCA1 and BRCA2 gene mutation carriers aged 30–60 years or women who have a 50% chance of carrying such a mutation [14-16]. For women with a familial risk, from families without a proven genetic predisposition, results are inconclusive [17,18]. Since previous screening studies have performed MRI and mammography simultaneously the difference in stage of the tumours when detected by mammography alone is not known. A randomized controlled trial is therefore needed.

Apart from a positive family history and age, high breast tissue density is a well documented risk factor for breast cancer. Breast density increases breast cancer incidence significantly [19,20]. At the same time, high mammographic density impairs the sensitivity of mammography [19-22], but far less the sensitivity of MRI [23]. The lower sensitivity of mammography in dense breasts is most likely caused by a masking effect, rather than by a higher tumour growth rate in denser tissue [21,24]. Breast density is high or very-high in about 50-74% of women between 40 to 49 years of age, whereas only 20-44% of women in their 60s have dense or extremely dense breast tissue [25,26]. This dual effect of breast density on cancer incidence and sensitivity of mammography results in women with the highest risk being screened with a tool with limited effectiveness: mammography.

To the best of our knowledge, no study has been published assessing the cost-effectiveness of MRI specifically in women with a familial risk for breast cancer, without a known genetic predisposition. Therefore, guidelines for breast cancer screening for women with a familial risk vary widely internationally and are weakly underpinned. The 2008 American Cancer Society and 2010 American College of Radiologists guidelines advise MRI screening for women with a familial cumulative lifetime risk (CLTR) > 20% [18], while the Dutch guidelines advise screening with mammography only [17].

Robust cost-effectiveness analyses cannot be based on the published studies, as all had a paired design (i.e. all participants received both mammography and MRI). These studies cannot examine the improvement in tumour stage at diagnosis, as one cannot know in what stage the tumour would have been diagnosed by either test alone. A randomized controlled trial is needed for a valid answer to these questions.

Furthermore, cost-effectiveness of either imaging technique may vary across categories of mammographic density. Breast density has not yet been evaluated as a parameter to identify sub-groups of women with a familial risk, for whom MRI is cost-effective. A prospective randomized trial in women with increased breast cancer risk, taking breast density into account, will give robust evidence on which screening tool, MRI or mammography, is best suited for a particular woman. These issues are addressed in the Familial MRI Screening study (FaMRIsc).

Methods/Design
Trial design
The FaMRIsc study is a multicentre, randomized controlled trial (RCT), with balanced randomisation (1:1), and a parallel group design conducted in the Netherlands. The study is in compliance with the Helsinki declaration and ethical approval has been granted on 8 November 2010 by the Institutional Review Board of the Erasmus University Medical Centre, Rotterdam, the Netherlands (reference-number: MEC-2010-292).

Participants
Eligible participants are women aged 30–55 years with a cumulative lifetime risk (CLTR) of >20% because of a familial predisposition according to the modified tables of Claus [1,27] or as assessed at a Clinical Genetics Centre. BRCA1 and/or BRCA2 mutation carriers or women with a 50% likelihood of such a mutation are excluded, since MRI screening is already advised for these women by the American Cancer Society (ACS), the American College of Radiologists (ACR), the United Kingdom’s NICE guideline and the European guideline of the European Society of breast imaging (EUSOBI) [18,28-30]. Exclusion criteria are previous invasive cancer
(potentially of influence on survival data), and a contra-indication for contrast-enhanced MRI (decreased creatinin clearance, metal implants or claustrophobia).

**Study settings**

Participants are recruited from outpatient breast or family cancer clinics at all eight academic medical centres in the Netherlands and the Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital (Additional file 1). Women who are already in a screening programme because of an increased familial risk and meeting inclusion criteria are sent study information 2 weeks before a scheduled visit. Women who meet all criteria and visit the outpatient clinic for an initial screening are given information on site.

**Interventions**

After informed consent is obtained participants are randomized through a computer-generated randomization sequence with stratification for centre, in one of the two groups.

Group 1 receives screening according to the 2012 Dutch guidelines [17] with yearly mammography and clinical breast examination (CBE).

Group 2 is screened with yearly MRI and CBE, and mammography biennially (Figure 1). Additional investigations are performed if deemed necessary due to findings at clinical examination, on mammography or MRI. Mammography still has a place in both arms, since DCIS is generally easier to detect with mammography [8,10,31-33], although in one study MRI was found to detect more aggressive grade III DCIS than mammography [34]. In the intervention arm however, the frequency of mammography is reduced from annually to biennially. DCIS not detected by MRI will most likely be low-grade, progress slowly, and be detected by the next mammographic examination. Leaving out mammography every other year seems safe in the MRI arm and may prevent over diagnosis of low-grade DCIS. Mammographic examination is done using full field digital mammography (FFDM). All examinations are scored in a standardized way, according to the Breast Imaging Reporting and Data System (BI-RADS) mammography classification of the American College of Radiology [30]. To determine mammographic density an automated breast density measurement is done on raw data of the first FFDM of all participants [35,36]. Dynamic breast MRI with gadolinium-containing contrast medium is performed according to standard protocol. In premenopausal women, the MRI is performed between day 5 and 20 of the menstrual cycle [37].

**Outcomes**

Primary endpoints are the number and stage of detected breast cancers, both DCIS and invasive, in each arm. Secondary endpoints are the false-positive results in the screening arms, and the sensitivity and positive predictive value of both screening strategies. Furthermore, cost-effectiveness and breast cancer mortality reduction of both strategies will be assessed. All analyzes will also be performed stratified for mammographic density.

A positive screening test is defined as a mammographic or MRI examination with a BI-RADS score of 0, 3, 4, or 5 and/or a clinical breast examination classified as ‘suspicious’. Interval cancers are defined as tumours diagnosed after a negative screening examination but before the next scheduled screening examination. Sensitivity is calculated as the number of screen-detected tumours divided by the total of screen-detected and interval tumours. The positive predictive value of a screening strategy is calculated as the proportion of women with a positive screening test, which after pathology indeed proved to be breast cancer.

Prospective assessment of mortality reduction requires a very lengthy follow-up and a large study population, which may not be feasible. To study this issue we will start with a less costly and time-consuming approach and estimate mortality reduction through a micro-simulation model: MISCAN, a well-validated micro-simulation model, originally developed to estimate the cost-effectiveness of the population-based screening program in the Netherlands [38-40]. In the model, the natural history of breast cancer is modelled as a progression through 5 pre-clinical and invasive disease stages. At each pre-clinical stage, a tumour may either be clinically diagnosed or grow into the next pre-clinical stage. Screening may detect the tumour in a preclinical stage. Transition probabilities, stage durations and survival after clinical diagnosis or screen detection are based on data from the Dutch nation-wide screening program [41,42]. The improvement of prognosis after detection by screening is based on the long-term effects of Swedish trials [43-45]. A detailed description of the model has been published previously [39].

We will develop a family history risk model by using the number of women enrolled in the study, the age distribution at entry of the study, the duration of follow-up and the screening protocol, attendance and sensitivity of different screenings methods as inputs. The model will be calibrated using the number of screens, the number of screen detected cancers and interval cancers, the stage distribution and the age at diagnosis. Likelihood ratio tests will be used to compare the goodness of fit. Using the calibrated model, predictions of the number of screens, number of screen detected and interval cancers, the stage distribution, the mortality reduction and the life years gained will be made for the different screening arms in the study.

A cohort of 5 million women will be simulated. All costs and effects will be predicted for a life-time follow-
up. The costs will be presented in European currency (€). Cost-effectiveness ratios will be expressed as cost per life year gained (LYG). Costs and effects will be discounted at an annual rate of 3.5%.

Sample size/power calculation
Our primary aim is to detect a difference in tumour stage between the intervention and the current practice group. In the Dutch MRI Screening Study (MRISC) study, conducted from 1999 to 2007, over 1500 women with familial risk were included in the 6 participating centres [11]. The incidence rate in this risk group was 7/1000 women years screened. Since the FaMRIsc study will have three more participating centres we intend to include 2000 women. We expect to detect about 50 breast cancers (both DCIS and invasive) in 4 years. With this number we are able to detect a difference in tumour size of 8 mm (SD tumour size: 9 mm) as statistically significant (two sided alpha =0.05) with a power of 80%. Eight mm is considered to be a clinically relevant difference.

Stopping guidelines
The accrual will be evaluated after two years. If adequate inclusion numbers cannot be achieved, appropriate measures will be taken in the remaining two years, consisting of expansion of the number of participating centres or longer continuation of the study.

Statistical methods
Primary outcome will be incidence and the difference in mean tumour size at diagnosis between the two arms. If normally distributed, this will be tested by means of the independent samples (unpaired) $t$-test. If not normally distributed, medians will be estimated and differences between distributions will be tested with the non-parametric Mann–Whitney $U$ test.

Breast cancer incidence rates will be calculated as the total number of breast cancers detected per 1000 woman-years at risk. This will be calculated both including and excluding DCIS. Differences between these proportions will be compared using a chi-square test or Fisher’s exact test as appropriate.

All tests will also be performed stratified by mammographic density to examine the influence of density on the efficacy of MRI screening versus usual care. The influence of breast density on detection rates, tumour stage and false positive results in both arms will be analysed by means of analysis of variance (ANOVA).
Discussion
Twenty-five percent of all breast cancers occur before age 50 and especially familial breast cancer is seen at younger ages [2]. A randomized controlled trial can provide the best evidence for any breast cancer mortality reduction attributable to digital mammography or MRI screening in this population.

Studies that offered MRI and mammography screening simultaneously have several shortcomings due to their paired design. Sensitivity of neither test without the other can be assessed. Nor the stage in which either test separately would have detected tumours.

With the results of our study we will be able to estimate the mortality reduction for screening women with familial risk with either digital mammography or additional MRI.

Furthermore, we will be able to assess whether mortality reduction by earlier detection differs with increasing breast density between screening with digital mammography or with additional MRI.

Breast density may be a key discriminator for choosing the optimal screening strategy below age 50 years for women with familial risk. If we can assess this, personalized cancer screening can be offered, based on a woman’s age, risk and breast density. This may optimize mortality reduction, whilst possibly decreasing over diagnosis. Compliance to screening will be best if there is convincing evidence that the most effective tool with the lowest side-effects is offered.

Additional file

Additional file 1: Academic Medical Centres participating in the FaMRIsc in the Netherlands.

Abbreviations
ANOVA: Analysis of variance; ACS: American Cancer Society; ACR: American College of Radiologists; BI-RADS: The Breast Imaging Reporting and Data System; CBE: Clinical Breast examination; CLTR: Cumulative Lifetime Risk; DCIS: Ductal Carcinoma In Situ; EUSOBI: European Society Of Breast Imaging; FaMRIsc: Familial MRI Screening Study; FFDM: Full Field Digital Mammography; LYG: Life Year Gained; MISCAN: Microsimulation Screening Analysis; MRI: Magnetic Resonance Imaging; MRISC: MRI Screening Study; RCT: Randomized Controlled Trial.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MMAT-L is the scientific coordinator of this research and designed the study. MMAT-L, IMO, HIK and SS applied for funding: MMAT-L and SS have drafted the manuscript with critical input from all other authors who have read, and approved the final manuscript. All authors are involved in data acquisition.

Acknowledgements
This study was supported by funds of: The Dutch Cancer Society (DDHK 2009–4491), ZonMW grant no. 200320012, A Sisters Hope and Stichting Coolingsel.

Author details
1Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands. 2Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. 3Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands. 4Department of Radiology, Academic Medical Centre, Amsterdam, Netherlands. 5Department of Medical Genetics, University Medical Centre, Utrecht, Netherlands. 6Department of Surgery, Academic Hospital, Maastricht, Netherlands. 7Department of Surgery, Radboud University, Nijmegen, Netherlands. 8Department of Public Health, Erasmus University Medical Centre, Rotterdam, Netherlands. 9Department of Medical Oncology, Erasmus University Medical Centre-Daniel den Hoed Cancer Centre, Rotterdam, Netherlands. 10Department of Genetics, University of Groningen, UMCG, Groningen, Netherlands. 11Department of Radiology, Erasmus University Medical Centre, Rotterdam, Netherlands.

Received: 14 August 2012 Accepted: 20 September 2012
Published: 2 October 2012

References
1. Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994, 73(2):653–651.
2. Brandt A, Bermejo JL, Sundquist J, Hemminki K: Age of onset in familial breast cancer as background data for medical surveillance. Br J Cancer 2010, 102(1):42–47.
3. Margolin S, Johansson H, Rutqvist LE, Aornander T: Familial history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam Cancer 2006, 5(4):309–321.
4. Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, Coleman MP, Grosc Laudie P, Martinez C, Bell J, et al: Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 2003, 106(4):416–422.
5. Maurice A, Evans DG, Affen J, Greenhalgh R, Dufy SW, Howell A: Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. Int J Cancer 2012, 131(2):417–425.
6. teams FHc: Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol 2010, 11(12):1127–1134.
7. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M: Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000, 36(4):514–519.
8. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabo A, Apold J, Staane P, Mollier P: Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007, 16(4):367–374.
9. Kuhl C, Weigel S, Schrading S, Anand B, Bie ling H, Konig R, Tombach B, Leutner C, Rieber-Brambilla A, Nordhoff D, et al: Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010, 28(9):1450–1457.
10. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebisch I, Hoff RJ, Kessar P, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365(9473):1769–1773.
11. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Wobbes T: Surveillance of BRCA1 and BRCA2 mutation carriers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010, 28(36):5265–5273.
12. Warnier E, Plevier DB, Hill KA, Causer PA, Zoubotis JT, Long RA, Cutara MR, DeBoer G, Voller ML, Messner SJ, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292(11):1317–1325.
13. van der Velden AP S, Schlooz-Vries MS, Boetes C, Wobbes T: Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review. Am J Surg 2009, 198(2):262–269.
14. Griebich J, Brown J, Boggs C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hannaur J, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 2006, 95(7):801–810.

15. Lee JM, McIlroy PM, Kong CY, Kopans DB, Ryan PD, Zhao EM, Halpern EF, Gazelle GS. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology 2010, 254(3):793–800.

16. Plevriski SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stodackle FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006, 295(20):2374–2384.

17. Richteljmammacarcinoom. http://www.oncoline.nl/upload/docs/mammacarcinoom/mammacarcinoom.pdf.

18. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75–89.

19. Kielkowsk K. The mammogram that cried Wolfe. N Engl J Med 2007, 356(8):297–300.

20. Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, Mattison J, Cook M, Warsi I, Evans DG, et al. Mammographic density and age: implications for breast cancer risk. Eur Radiol 2007, 17(7):1792–197.

21. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Obdeijn IM, et al. Mammographic density as indicator for the breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 2006, 66(3):1806–1872.

22. Ford NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Huislop G, Chiarrella A, Minkin S, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2006, 355(3):227–236.

23. Thompson DJ, Leach MO, Kwan-Lim G, Gayther SA, Ramsus SJ, Warsi I, Lennard F, Khazem M, Bryant E, Reed S, et al. Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Res 2009, 11(6):R80.

24. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock JS, Rammus SJ, Lennard F, Khazem M, Bryant E, Reed S, et al. Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Res 2009, 11(6):R80.

25. Titus-Linthorst MM, Obdeijn IM, Hop WC, van Houwelingen JC, van de Vijver MJ, van Diemen-Homan JE, Bakker E, Zonderland HM, Coerkamp EG, Hermans J, van even GJ, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007, 370(9686):485–492.

26. Eltertise AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy, tamoxifen and raloxifene on mammographic breast density, assessed by an automated quantitative method. Breast 2008, 115(6):773–779.

27. van Engeland S, Snoeren PR, Huismen H, Boetes C, Karssemeijer N. Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging 2006, 25(3):273–282.

28. Boetes C, Stooudenrijck MJ. Imaging in screening women at increased risk for breast cancer. Magn Reson Imaging Clin N Am 2001, 9(2):357–372 v4.

29. de Koning HJ. Mammographic screening: evidence from randomised controlled trials. Ann Oncol 2003, 14(8):1185–1189.

30. Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME, Birnie E, Buigt-van der Woude T, Mali WP, de Koning HJ, Buikens E. Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open breast biopsy. Br J Cancer 2004, 90(2):393–392.

31. Rijnberger AJ, van Oortmarssen GJ, Roer, Draisma G, To T, Miller AB, de Koning HJ. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. Int J Cancer 2004, 110(5):756–762.

32. (NETB) NETfBcs: National evaluation of breast cancer screening in the Netherlands - eleventh evaluation report. Rotterdam: Department of Public Health, Erasmus MC, 2005.

33. Berry DA, Cronin KA, Plevriski SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784–1792.

34. Bjarndal N, Bjorneld L, Warwick J, Sala E, Duffly SW, Nyström L, Walker N, Cahill E, Eriksson O, Haifston LO, et al. The Gothenburg Breast Screening Trial. Cancer 2003, 97(10):2387–2396.

35. Nyström L, Andersson L, Bjarndal N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359(9310):909–911.

36. Tabar L, Yen MF, Vikat B, Chen HH, Smith RA, Duffly SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003, 361(9367):1405–1410.